Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.
BACKGROUND AND AIMS: The aim was to determine the toxicity, clinical and immune responses to the murine monoclonal anti-carcinoembryonic antigen (CEA) antibody, PR1A3, in patients with advanced colorectal cancer. MATERIALS AND METHODS: Fifteen patients with advanced colorectal cancer received eithe...
Main Authors: | Zbar, A, Thomas, H, Wilkinson, R, Wadhwa, M, Syrigos, K, Ross, E, Dilger, P, Allen-Mersh, T, Kmiot, W, Epenetos, A, Snary, D, Bodmer, W |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
CEA-targeted monoclonal antibody therapy in colorectal cancer
by: Conaghan, P, et al.
Published: (2009) -
Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
by: Ashraf, S, et al.
Published: (2008) -
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
by: Wilkinson, R, et al.
Published: (2001) -
CEA monitoring in colorectal cancer is not a waste of time.
by: Mant, D, et al.
Published: (2014) -
Optimization of serum free medium for the production of humanized anti-cea monoclonal antibody.
by: Ab Latif, Nurzila
Published: (2011)